What development phase is ILUNOCITINIB in?

ILUNOCITINIB is FDA-approved (marketed).

What are the side effects of ILUNOCITINIB?

Common side effects include Vomiting or nausea, Diarrhea, Lethargy, Otitis externa, Anorexia, Dermal growth (e.g., cyst, papilloma).

Last reviewed 2026-04-20 · How we verify

ILUNOCITINIB

FDA-approved active Small molecule Quality 6/100

Ilunocitinib is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging its current revenue streams. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	ILUNOCITINIB
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

Vomiting or nausea
Diarrhea
Lethargy
Otitis externa
Anorexia
Dermal growth (e.g., cyst, papilloma)
Epiphora or ocular discharge
Coughing or wheezing, including respiratory infections
Bacterial skin infection
Elevated liver enzyme(s)
Urinary tract infection
Upset stomach, including flatulence and abdominal pain

Serious adverse events

Metastatic neoplasia (hemangiosarcoma)
Mast cell tumor
Systemic fungal infection
Neutropenia with clinical urinary tract infection
Otitis interna with vestibular disease
Eyelid mass with bacterial blepharitis
Histiocytoma enlargement (non-resolving)
Thrombocytopenia
Traumatic tendonitis progressing to serious infection
Lymphocytosis worsening